Kelly Lawrence W & Associates Inc. CA Makes New Investment in Repligen Corporation $RGEN

Key Points

• Kelly Lawrence W & Associates acquired 59,250 Repligen shares worth approximately $8.1 million, giving the biotechnology company a 1.7% weighting in its portfolio. Institutional investors and hedge funds collectively own 97.64% of Repligen.
• Repligen exceeded quarterly expectations with EPS of $0.54 versus the $0.45 consensus and revenue of $204.13 million, up 11.9% year over year. The company maintained fiscal 2026 EPS guidance of $2.03–$2.09.
• Analysts broadly rate the stock a “Buy”, with a consensus price target of $166.43, while shares recently traded at $181.62. The valuation remains elevated, with a P/E ratio of 248.79; meanwhile, the CFO sold 733 shares, reducing his holdings by 3.65%.

Kelly Lawrence W & Associates Inc. CA acquired a new stake in shares of Repligen Corporation (NASDAQ:RGEN - Free Report) in the second quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor acquired 59,250 shares of the biotechnology company's stock, valued at approximately $8,084,000. Repligen makes up about 1.7% of Kelly Lawrence W & Associates Inc. CA's holdings, making the stock its 20th biggest position. Kelly Lawrence W & Associates Inc. CA owned 0.10% of Repligen at the end of the most recent quarter.

Several other hedge funds and other institutional investors also recently made changes to their positions in the company. United Capital Financial Advisors LLC acquired a new stake in shares of Repligen during the third quarter valued at approximately $368,387,000. Opti Capital Management LP purchased a new stake in shares of Repligen in the 4th quarter valued at approximately $2,399,209,000. Maverick Capital Ltd. acquired a new position in Repligen in the 1st quarter worth approximately $178,946,000. Wasatch Advisors LP purchased a new position in Repligen during the 1st quarter worth approximately $146,513,000. Finally, Price T Rowe Associates Inc. MD grew its position in Repligen by 31.1% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 4,599,061 shares of the biotechnology company's stock worth $753,603,000 after purchasing an additional 1,091,683 shares in the last quarter. 97.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In related news, CFO Jason K. Garland sold 733 shares of Repligen stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $145.00, for a total transaction of $106,285.00. Following the completion of the sale, the chief financial officer owned 19,359 shares of the company's stock, valued at approximately $2,807,055. This trade represents a 3.65% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Corporate insiders own 0.60% of the company's stock.

Repligen Stock Up 0.3%

Repligen stock opened at $181.62 on Tuesday. Repligen Corporation has a twelve month low of $100.99 and a twelve month high of $188.73. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.64 and a current ratio of 9.05. The firm has a market cap of $10.25 billion, a PE ratio of 248.79, a P/E/G ratio of 3.31 and a beta of 1.03. The firm's 50 day moving average price is $148.17 and its two-hundred day moving average price is $131.97.

Repligen (NASDAQ:RGEN - Get Free Report) last issued its earnings results on Tuesday, July 28th. The biotechnology company reported $0.54 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.45 by $0.09. Repligen had a net margin of 5.29% and a return on equity of 5.30%. The company had revenue of $204.13 million during the quarter, compared to analyst estimates of $201.59 million. During the same quarter last year, the business posted $0.26 EPS. The company's revenue for the quarter was up 11.9% on a year-over-year basis. Repligen has set its FY 2026 guidance at 2.030-2.090 EPS. On average, research analysts predict that Repligen Corporation will post 2.06 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on RGEN. Barclays boosted their target price on shares of Repligen from $145.00 to $160.00 and gave the company an "overweight" rating in a research note on Wednesday, May 6th. Citigroup upgraded Repligen to a "buy" rating in a report on Tuesday, July 7th. Jefferies Financial Group reissued a "hold" rating and set a $142.00 price target on shares of Repligen in a research report on Tuesday, May 5th. JPMorgan Chase & Co. increased their price objective on Repligen from $165.00 to $175.00 and gave the stock an "overweight" rating in a research note on Wednesday, July 29th. Finally, Benchmark upgraded Repligen from a "hold" rating to a "buy" rating and set a $185.00 price objective for the company in a research report on Tuesday, July 7th. Three analysts have rated the stock with a Strong Buy rating, twelve have issued a Buy rating and three have issued a Hold rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Buy" and a consensus target price of $166.43.

About Repligen

Repligen Corporation NASDAQ: RGEN is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen's offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company's core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source